ArticleeLife2018
Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Diverse germline-targeting HIV Env immunogens select for distinct mutations in the same knock-in mice B cell receptors.Nature communications · 2026Article
- Funding Strategies to Foster Enabling Basic Science Research in the Development of an HIV Vaccine.Current HIV research · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.The Journal of experimental medicine · 2025Article
- Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.PLoS pathogens · 2025Article
- Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.Journal of virology · 2024Article
- Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.Science immunology · 2024Article
- Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023Review
- A classification algorithm based on dynamic ensemble selection to predict mutational patterns of the envelope protein in HIV-infected patients.Algorithms for molecular biology : AMB · 2023Article
- Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates.Nature communications · 2023Article
- Article
- HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design.Nature communications · 2022Article
- Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.Immunity · 2022Article
- In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.PLoS pathogens · 2021Article
- HIV-1 Envelope Conformation, Allostery, and Dynamics.Viruses · 2021Review
- Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.Cell reports · 2021Article
- Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.Nature structural & molecular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Andrew J BorstDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID https://orcid.org/0000-0003-4297-7824
Connor E WeidleVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Matthew D GrayVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Brandon FrenzDepartment of Biochemistry, University of Washington, Seattle, United States.
Joost SnijderDepartment of Biochemistry, University of Washington, Seattle, United States.
M Gordon JoyceVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Ivelin S GeorgievVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Guillaume Be Stewart-JonesVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Andrew T McGuireVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Frank DiMaioDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID http://orcid.org/0000-0002-7524-8938
Leonidas StamatatosVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Marie PanceraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID http://orcid.org/0000-0002-6019-8675
University of Washington · USNational Institutes of Health · USFred Hutch Cancer Center · US
Funding
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class AnU19AI109632 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2014 to 2020
$25.1MDesign Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MStructure/function studies of immunogen recognition by anti-HIV antibody b12P01AI094419 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2011 to 2015
$10.6MTRAINING IN MOLECULAR BIOPHYSICST32GM008268 · NIGMS · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M, ZHENG, NING · 1988 to 2023
$8.6MDefining BCR evolution during immunizationR01AI104384 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2013 to 2021
$5.9MMonitoring the development of anti-Env Abs during HIV infectionR01AI081625 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2010 to 2020
$5.8MWest/Midwest Consortium for High-Resolution Cryo Electron MicroscopyU24GM116792 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGBANDJE-MCKENNA, MAVIS, DOKLAND, TERJE · 2016 to 2020
$3.0MProtein structure determination from low-resolution experimental dataR01GM123089 · NIGMS · UNIVERSITY OF WASHINGTON · PI DIMAIO, FRANK P · 2017 to 2025
$2.6MStructural Studies of Coronavirus Fusion ProteinsR01GM120553 · NIGMS · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2016 to 2020
$1.7MHIGH-END CRYOEM INSTRUMENT FOR UCLA ELECTRON IMAGING CTR FOR NANOMACHINES: AIDSS10RR023057 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2006 to 2006
$1.6MDirect Detection Device for atomic resolution cryoEM of macromolecular complexesS10OD018111 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2014 to 2014
$598kNational Institute of Allergy and Infectious Diseases P01 AI094419National Institute of Allergy and Infectious Diseases R01 AI081625National Institute of Allergy and Infectious Diseases R01AI081625National Institute of Allergy and Infectious Diseases R01 AI104384National Institute of Allergy and Infectious Diseases U19 AI109632NCRR NIH HHS S10 RR023057NIAID NIH HHS P01 AI094419NIAID NIH HHS R01 AI081625NIAID NIH HHS R01 AI104384NIAID NIH HHS U19 AI109632NIGMS NIH HHS R01 GM120553NIGMS NIH HHS R01GM120553NIGMS NIH HHS R01 GM123089NIGMS NIH HHS T32 GM008268NIGMS NIH HHS T32GM008268NIGMS NIH HHS U24 GM116792NIH HHS S10 OD018111
Abstract
VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4
Indexed as
Protein MultimerizationAmino Acid SequenceAntibodiesGerm CellsGlycosylationHEK293 CellsHIV-1HIV Envelope Protein gp120HumansImmunoglobulin Fab FragmentsImmunoglobulin GModels, MolecularPolysaccharidesProtein BindingProtein Structure, SecondaryAntibodiesHIV Envelope Protein gp120Immunoglobulin Fab FragmentsImmunoglobulin GPolysaccharidescryoEMcrystallographyfusion proteinglycan shieldHIVHIV envelopemolecular biophysicsstructural biologyvirusVRC01
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.